医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Lumos Diagnostics Appoints Three Industry Leaders as Independent Directors

2021年05月06日 AM05:30
このエントリーをはてなブックマークに追加


 

SARASOTA, Fla.

Lumos Diagnostics announced today the expansion of its board with the appointment of three new independent directors to support the continued growth of the company’s rapid point-of-care diagnostic products and services business. Bronwyn Le Grice, Lawrence Mehren and Catherine Robson will join Executive Chair Sam Lanyon and and Executive Director Rob Sambursky, MD.

“On behalf of the entire company, I am delighted to welcome Bronwyn, Larry and Catherine to the Lumos Board of Directors,” said Sam Lanyon, executive chair of Lumos Diagnostics. “Together, they offer extensive and diverse operational experience in growing diagnostic companies, strong knowledge of equity markets and broad corporate governance expertise. Lumos will benefit from their guidance as we expand our commercial infrastructure and global market access to novel point-of-care tests.”

Bronwyn Le Grice brings expertise in digital health and public market knowledge. She has more than eighteen years executive experience in the health technology sector including venture capital, corporate development and industry advocacy. In 2017, Ms. Le Grice founded ANDHealth, Australia’s only dedicated digital health accelerator and commercialization support organization.

Lawrence Mehren provides diagnostic operational proficiency and public market experience. He served as the Chief Executive Officer and a Director of Accelerate Diagnostics (Nasdaq AXDX) from 2012 to 2020. Before this, Mr. Mehren served as Senior Vice President and Chief Financial Officer of Ventana Medical Systems, Inc. from 2007 until 2008 and as Head of Global Business from 2008 until 2011.

Catherine Robson expands Lumos’ financial capabilities and corporate governance experience. Catherine founded Affinity Private, a financial services firm and has non-executive director experience at Greater Bank, SCALE Investors and on ASX-listed Equity Trust Limited (EQT) Holdings Limited. She was previously a member of both the EQT Board Risk Committee and the Board Remuneration, Human Resources and Nominations Committee.

Lumos Board Executive Chair Sam Lanyon has more than twenty-five years of experience in business strategy, executive sales and operational management with a demonstrated track record in the global commercialization of technology rich healthcare products. He also serves as Co-CEO and co-founder of Planet Innovation.

Executive Director Rob Sambursky, MD, is one of the original founders and former executives of RPS Diagnostics, which merged with Lumos Diagnostics in 2019, and currently leads Lumos as its President and Chief Executive Officer. In addition to his product development and commercial experience, he has a strong scientific and clinical background in medical sciences, ophthalmology and infectious disease.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid, cost-effective and complete point-of-care (POC) diagnostic test solutions to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures and commercializes novel, Lumos-branded POC tests that target infectious and inflammatory diseases with unmet diagnostic needs. For more information visit lumosdiagnostics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210505006077/en/

CONTACT

Media Contact (Global):

Laura Lovejoy Sambursky

Saranova, LLC

communications@lumosdiagnostics.com

+1.941.928.9025

Media Contact (Australia):

Cristina Fletcher

WE Communications Australia

WE-AUPlanetInnovation@we-worldwide.com

+61.481.353.692

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 亚马逊与美国国家安全委员会携手开展业界首创合作项目,以解决美国常见的工伤问题
  • Aragen Announce Multi-Year Partnership With FMC Corporation, Aims at Accelerating Agro-Chemical Pipeline
  • 片肺換気中の高酸素血症介在疾患の罹患率にORiを指針とする酸素需要評価が及ぼす影響についての新研究
  • セルトリオン、抗COVID-19モノクローナル抗体治療剤「Regdanvimab(CT-P59)」の グローバル第3相臨床試験結果を発表
  • 沃特世推出SELECT SERIES MRT多反射飞行时间质谱平台,树立高分辨质谱性能新标杆